Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883701 | 0.84 | PTGDR2 (0.59) | PTGDR2ALDH1A1CYP1A2CYP2C19TSHR | |
| SCHEMBL22216884 | 0.80 | LMNA (0.47) | PTGDR2ALDH1A1CYP1A2CYP2C19TSHR | |
| SCHEMBL5882295 | 0.79 | ALDH1A1 (0.72) | PTGDR2ALDH1A1CYP1A2CYP2C19TSHR | |
| SCHEMBL31327406 | 0.78 | ALDH1A1 (0.37) | PTGDR2ALDH1A1CYP1A2CYP2C19ERN1 | |
| SCHEMBL4055189 | 0.77 | GAA (0.51) | PTPN1ERN1 | |
| SCHEMBL23111641 | 0.75 | PTGDR2 (0.57) | PTGDR2ALDH1A1TSHRPOLBTDP1 | |
| SCHEMBL14059589 | 0.75 | ALDH1A1 (0.35) | PTGDR2ALDH1A1CYP1A2CYP2C19ERN1 | |
| SCHEMBL30673247 | 0.74 | ERN1 (0.50) | ALDH1A1CYP1A2CYP2C19TSHRTDP1 | |
| SCHEMBL4599553 | 0.74 | ERN1 (0.50) | ALDH1A1CYP1A2CYP2C19TSHRTDP1 | |
| SCHEMBL29951244 | 0.73 | ERN1 (0.50) | PTGDR2ALDH1A1CYP1A2CYP2C19TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340529-B2 | Triazolones as fatty acid synthase inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-05-17 | — | — | US | disclosed |
| US-8802864-B2 | Triazolones as fatty acid synthase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140100213-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| EP-2538787-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-12-13 | — | — | US | disclosed |
| WO-2011103546-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140100213-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | PTGDR2 1840/4885ALDH1A1 629/4885CYP1A2 388/4885 |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | PTGDR2 1306/4885ALDH1A1 410/4885CYP1A2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.